Anti‑inflammatory effects of Perilla frutescens leaf extract on lipopolysaccharide‑stimulated RAW264.7 cells
- Authors:
- Published online on: June 5, 2014 https://doi.org/10.3892/mmr.2014.2298
- Pages: 1077-1083
Abstract
Introduction
The leaves of Perilla frutescens are commonly used as decorative elements in Asia, including China, Japan and Taiwan. Dried red Perilla leaves are also used as ‘soyou’ in Chinese herbal medicine and are components of ‘saiboku-to’, which is a Japanese herbal formula that is commonly used to treat asthma. Previous studies have reported that Perilla frutescens leaf extracts (PLE) display a range of biological activities, including inhibition of tumor necrosis factor (TNF)-α (1), suppression of IgA nephropathy (2), and anti-inflammatory and anti-allergic activity (3,4). However, the mechanisms underlying the anti-inflammatory properties of PLE are not well understood.
Inflammation is a response of organisms to pathogens and chemical or mechanical injury. Inflammatory response and tissue damage are induced by inflammatory mediators generated through upregulation of a number of inducible genes, including inducible nitric oxide (iNOS), cyclooxygenase (COX)-2, interleukin (IL)-6 and IL-8. Nitric oxide (NO) is a messenger molecule that has critical functions in vascular regulation, host immune defense, neuronal signal transduction, and other pathways (5–7). NO is produced from the conversion of L-arginine to L-citrulline by the nitric oxide synthase (NOS) in the presence of oxygen and NADPH (8). NOS is inducible in macrophages and hepatocytes, and is activated following infection (9). Therefore, inducible (i)NOS-derived NO is an ubiquitous mediator of a wide range of inflammatory conditions, and its expression level reflects the degree of inflammation, thus providing a measure of the inflammatory response (10,11). COX-2 also participates in immune system modulation and is involved in pathophysiological events (12). COX-2 is not expressed or is slightly detectable in most tissues under normal conditions; high expression of COX-2 following induction by pro-inflammatory mediators such as bacterial lipopolysaccharide (LPS), is involved in the pathogenesis of sepsis and inflammation (13,14). In addition, compounds interfering with both iNOS and COX-2 generally act as inhibitors of a transcription factor required for iNOS and COX-2 expression, nuclear factor (NF)-κB (15).
Macrophages play a crucial role in eliciting NF-κB-related cascades at the acute phase of the inflammatory response. LPS stimulation of mouse macrophages leads to increased phosphorylation and activation of mitogen-activated protein kinases (MAPKs), such as extracellular-signal-regulated kinase (ERK)1/2, and c-Jun N-terminal kinase (JNK) (16). Therefore, the development of specific drugs to inhibit the production of these inflammatory modulators may be effective in the treatment of inflammatory diseases. In the present study, we investigated the anti-inflammatory effects and the underlying mechanism of a P. frutescens leaf extract (PLE). Specifically, we studied the regulation of gene expression of iNOS, COX-2, and pro-inflammatory cytokines in RAW264.7 cells stimulated with LPS.
Materials and methods
Chemicals and reagents
Aprotinin, leupeptin, LPS, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), penicillin, streptomycin and other chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and supplements for cell culture were purchased from Gibco-BRL (Gaithersburg, MD, USA). Antibodies targeting phosphorylated Erk1/2 (p-Erk1/2), total Erk1/2 (t-Erk1/2), phosphorylated JNK (p-JNK), total JNK (t-JNK), phosphorylated p38 (p-p38), total p38 (t-p38), IκBα and NF-κB (p65 subunit) were purchased from Cell Signaling Technologies (Beverly, MA, USA). The antibody targeting the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was purchased from Sigma-Aldrich. HRP-conjugated secondary antibodies targeting mouse and rabbit IgGs were purchased from Abcam (Cambridge, UK). The murine macrophage RAW264.7 cell line was obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA).
Preparation of P. frutescens leaf extract (PLE)
Perilla frutescens plants were purchased from a certified herbal pharmacy (Chung-Yi Chinese Herbal Medicine Pharmacy, Taichung, Taiwan). After dehydration, 100 g of the leaves were homogenized, and the powder was passed through a mesh (0.05 mm). The filtered powder was resuspended into 1 liter of 100% methanol and stirred at room temperature for 24 h. Following filtration on a Whatman no. 1 filter paper, the solution was lyophilized. Stock solution (20 mg/ml) of the extract was prepared in dimethylsulfoxide, and stored at −20°C until further use.
Cell cultures and treatment
The RAW264.7 cells were incubated in DMEM supplemented with 0.1% sodium bicarbonate, 2 mM glutamine, penicillin G (100 U/ml), streptomycin (100 μg/ml) and 10% FBS, and were maintained at 37°C in a humidified incubator containing 5% CO2. Following pre-incubation with different concentrations of PLE for 4 h, 1 μg/ml LPS was added and then incubated for 2 h (NO assay), 3 h (RT-PCR and qRT-PCR analysis), or 24 h (cell viability assay and cell morphology analyses).
Cell viability assay
Cell viability was determined by an assay based on the mitochondrial-dependent reduction of MTT to formazan. Briefly, 10 μl of MTT solution (5 mg/ml in DMEM) were added to the cell supernatant and incubated for 4 h at 37°C. After removal of the medium, 2-propanol was added to lyse the cells and to solubilize the formazan. The optical density of formazan was measured at 570 nm using a microplate reader (Benchmark; Bio-Rad Laboratories, Hercules, CA, USA). The optical density of formazan generated by untreated cells was used to determine the 100% viability.
RNA extraction, reverse transcription polymerase chain reaction (RT-PCR) and quantitative (q)RT-PCR
Total RNA was isolated from individual samples, according to the manufacturer’s instructions, using the RNeasy kit (Qiagen, Valencia, CA, USA). The purified RNA was used as a template to generate cDNA using the RevertAid™ First Strand cDNA Synthesis kit (Fermentas Life Sciences, St. Leon-Rot, Germany). The primer sequences used for RT-PCR and qRT-PCR are listed in Table I. RT-PCR experiments were performed in triplicates for each sample. Amplifications were performed using the ABI PRISM 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA). For mRNA quantification, the FastStart Universal SYBR-Green Master mix (Roche Applied Science, Mannheim, Germany) was used. The cycle threshold (Ct) values were calculated using the ΔΔCT method, and relative expression values were expressed by normalizing to the expression of GAPDH. qRT-PCR experiments were performed in duplicates for each sample. The size of the PCR products was confirmed by agarose gel electrophoresis.
Table IPrimer sequences used for reverse transcription polymerase chain reaction (RT-PCR) and quantitative (q)RT-PCR. |
NO assay
The NO level in cell culture supernatants was determined using the Griess test. Briefly, cells were treated with 1, 5, or 15 μg/ml PLE for 1 h, followed by incubation with 1 μg/ml LPS for 24 h. Nitrite in the culture supernatants was mixed with the same volume of Griess reagent [1% sulfanilamide and 0.1% N-(1-naphthyl)ethylenediamine dihydrochloride in 5% phosphoric acid]. Absorbance was measured at 540 nm, and the nitrite concentration was determined using sodium nitrite (NaNO2) as a standard (17).
Enzyme-linked immunosorbent assay (ELISA)
To analyze the production of pro-inflammatory mediators, cells were seeded in 6-well plates at an initial density of 5×105 cells/ml, starved in serum-free medium for 16 h, pre-incubated with different concentrations of PLE (5, 10 and 20 μg/ml) for 1 h, then treated with 1 μg/ml LPS for 24 h. The supernatants were collected, and the concentrations of IL-6, IL-8 and TNF-α, as well as of prostaglandin E2 (PGE2) were determined using DuoSet ELISA kits and the Prostaglandin E2 Parameter Assay kit (R&D Systems, Abingdon, UK) respectively, following the manufacturer’s instructions.
Subcellular fractionation
Cells were washed with physiological saline and incubated with lysis buffer [10 mM HEPES, pH 7.6, containing 15 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 1 mM dithiothreitol, 0.05% v/v IGEPAL® CA-630, 1 mM phenylmethanesulfonyl fluoride (PMSF), 1 mM sodium orthovanadate, 50 mM sodium fluoride, 10 μg/ml leupeptin, and 10 μg/ml aprotinin] for 10 min. Following centrifugation at 2,500 × g for 10 min at 4°C, the supernatant was transferred into a new Eppendorf tube, further centrifuged at 20,000 × g for 15 min at 4°C, and the new supernatant was collected as the cytosolic fraction. The pellets containing the nuclei were washed with physiological saline, incubated with a nucleus lysis buffer (25 mM HEPES, pH 7.6, 0.1% v/v IGEPAL® CA-630, 1 M KCl, 0.1 mM EDTA, 1 mM PMSF, 1 mM sodium orthovanadate, 2 mM sodium fluoride, 10 μg/ml leupeptin, and 10 μg/ml aprotinin), and then centrifuged at 10,000 × g for 15 min at 4°C. The resulting supernatants were collected as the nuclear fraction.
Immunoblotting
Cells (5×105 cells/ml) were harvested, washed twice with ice-cold phosphate-buffered saline (PBS), and lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% v/v IGEPAL® CA-630, 1 mM PMSF, 1 mM sodium fluoride, and 10 μg/ml aprotinin and leupeptin). The cell lysates were centrifuged at 14,000 × g for 10 min at 4°C to remove the debris. The supernatants were collected and crude protein concentrations were determined using the BCA™ protein assay kit (Pierce, Rockford, IL, USA). Crude proteins (30 μg/lane) were electrophoresed and transferred onto a nitrocellulose membrane (Millipore, Bedford, MA, USA). After blocking with 5% w/v skimmed milk in PBS, the membrane was incubated for 2 h with a 1/1,000 dilution of the specific primary antibodies. Bound antibodies were detected using a 1/2,000 dilution of peroxidase-conjugated secondary antibodies (Abcam) and ECL chemiluminescence reagent (Millipore) as the substrate. Three independent experiments were performed, and results were quantified by densitometry.
Statistical analysis
Data were expressed as means ± standard deviation (SD) of the mean from three independent experiments. Statistical comparisons were performed by a one-way analysis of variance (ANOVA), followed by a Duncan multiple comparison test. Differences were considered statistically significant at P<0.05.
Results
Effects of PLE on viability of murine macrophage RAW264.7 cells
The cytotoxic effect of PLE on viability of RAW264.7 cells was investigated by the MTT assay. As shown in Fig. 1, the viability of RAW264.7 cells was determined following incubation with different concentrations (1, 5, 15, 30, 50 and 100 μg/ml) of PLE for 24 h. The results revealed that treatment with concentrations of 50 and 100 μg/ml PLE significantly decreased the viability of RAW264.7 cells (P<0.05) compared to control (untreated) cells, while lower concentrations (1, 5, 15 and 30 μg/ml) of PLE had no significant effect on viability of RAW264.7 cells.
PLE inhibits LPS-induced dendritic transformation of RAW264.7 cells
LPS is known to induce morphological transformation of macrophage RAW264.7 cells (18). Therefore, whether PLE affects the LPS-induced morphological changes of RAW264.7 cells was investigated. As shown in Fig. 2, LPS alone significantly induced the morphological transformation of RAW264.7 cells to dendritic cells, and this transformation was attenuated by PLE pretreatment in a dose-dependent manner. Further quantitative analysis revealed that LPS significantly increases the number of cells having a dendritic morphology to 27.0±0.5% (P<0.05 as compared to the control). When cells were pretreated with 10 or 15 μg/ml PLE and then treated with LPS, the number of cells with dendritic morphology was decreased to 13.6±1.6 and 9.4±0.6%, respectively (P<0.05 as compared to LPS treatment alone).
PLE inhibits LPS-induced mRNA expression and production of IL-6, IL-8 and TNF-α in RAW264.7 cells
To investigate whether PLE affects the expression of pro-inflammatory cytokines in LPS-stimulated macrophages, the mRNA levels of IL-6, IL-8 and TNF-α were determined in LPS-treated RAW264.7 cells. RT-PCR analysis revealed that LPS alone enhances the expression of IL-6, IL-8 and TNF-α, and this increase is reverted by pretreatment with PLE in a dose-dependent manner (Fig. 3A). Further quantitative analysis using qRT-PCR showed that treatment with LPS alone significantly increases the mRNA levels of IL-6, IL-8 and TNF-α, 3.9±0.4-, 13.8±1.5- and 5.4±0.3-fold respectively (Fig. 3B), as compared to the control (untreated cells). In RAW264.7 cells pretreated with 20 μg/ml PLE and then treated with 1 μg/ml LPS, the mRNA levels of IL-6, IL-8 and TNF-α were reduced 1.4±0.2-, 5.1±0.3- and 3.4±0.2-fold as compared to the control, respectively (P<0.005 as compared to LPS alone).
In addition to mRNA expression, LPS alone increased the protein production of IL-6, IL-8, and TNF-α in RAW264.7 cells (Fig. 3C) up to 135.7±18.9, 145.9±21.3 and 488.2±33.2 pg/ml/104 cells, respectively (P<0.05 as compared to the control). PLE pretreatment dose-dependently reduced the protein production of the tested cytokines (Fig. 3C) up to 59.3±5.6 (IL-6), 38.2±3.9 (IL-8) and 228.7±13.3 pg/ml/104 cells (TNF-α), respectively (P<0.05 as compared to LPS alone).
PLE inhibits LPS-induced mRNA expression of COX-2 and iNOS and the production of PGE2 and NO in RAW264.7 cells
COX-2 and iNOS are both critical enzymes associated with macrophage-mediated development and progression of inflammation (19–21); therefore, effects of PLE on the mRNA level of COX-2 and iNOS were analyzed and quantified in LPS-stimulated RAW264.7 cells. RT-PCR analysis showed that LPS treatment alone enhances the expression of COX-2 and iNOS, and this increase was reverted by pretreatment with PLE in a dose-dependent manner (Fig. 4A). Further quantitative analysis using qRT-PCR revealed that LPS alone significantly increases the mRNA levels of COX-2 and iNOS, 41.6±2.6- and 24.9±4.3-fold, respectively, as compared to the control (P<0.05). In RAW264.7 cells pretreated with 20 μg/ml PLE and then treated with 1 μg/ml LPS, the mRNA levels of COX-2 and iNOS were dose-dependently reduced (Fig. 4B) 11.6±1.5- and 6.6±1.2-fold as compared to the control, respectively (P<0.05 as compared to LPS alone).
Since mRNA expression of COX-2 and iNOS in RAW264.7 cells treated with LPS was inhibited by PLE pretreatment, the production of PGE2 and NO was further assessed. As shown in Fig. 4C and D, treatment with LPS alone significantly increased the concentrations of PGE2 and NO up to 310.9±22.5 pg/ml and 25.3±1.6 μM, respectively. Upon pretreatment with 10 or 20 μg/ml PLE, the concentration of PGE2 was reduced down to 168.1±9.2 pg/ml and 118.7±3.1 pg/ml, respectively, and the concentration of NO was decreased to 14.7±0.7 and 5.5±1.3 μM, respectively (P<0.05 as compared to LPS alone).
PLE inhibits phosphorylation of MAPKs, the degradation of IκBα and the nuclear translocation of NF-κB in LPS-stimulated RAW264.7 cells
Activation of MAPKs is known to be involved in LPS-induced production of pro-inflammatory cytokines (22–24). To investigate whether PLE regulates activation of MAPKs in response to LPS, the levels of phosphorylated ERK1/2, JNK and p38 were determined by immunoblotting in LPS-stimulated RAW264.7 cells. As shown in Fig. 5A, LPS alone considerably increased the phosphorylation of ERK1/2, JNK and p38 in RAW264.7 cells, and pretreatment with 5, 10 or 20 μg/ml PLE inhibited the LPS-induced phosphorylation of ERK1/2, JNK and p38 in a dose-dependent manner.
The transcription factor NF-κB plays a pivotal role in regulation of pro-inflammatory factors, and its nuclear translocation is associated with the expression of these factors (25). Thus, the effects of PLE on the cytosolic level of IκBα (that inhibits the nuclear translocation of NF-κB) and the nuclear level of NF-κB were subsequently investigated in RAW264.7 cells exposed to LPS. As shown in Fig. 5B, exposure of RAW264.7 cells to LPS led to an important decrease in the cytosolic IκBα level, accompanied by the expected increase in the nuclear NF-κB level. However, PLE pretreatment restored the LPS-decreased cytosolic IκBα level and reduced the nuclear NF-κB level that had been increased by LPS treatment, in a dose-dependent manner. These findings revealed that PLE inhibits not only the degradation of IκBα, but also the nuclear translocation of NF-κB.
Discussion
Macrophages were reported to be directly involved in the inflammatory response (26). One of the most important roles of macrophages is the production of various cytokines, reactive oxygen and nitrogen species, growth factors and chemokines as a response to signals such as bacterial LPS (27). Although the bioactive molecules produced by macrophages play important roles in inflammation, these molecules were also shown to exert undesirable effects to the cells (28). Therefore, modulation of these products may provide potential targets for the control of inflammatory diseases. IL-6 has various biological effects in a number of chronic endothelial dysfunctions such as modulation of hematopoiesis, proliferation and differentiation of lymphocytes, and induction of acute-phase reactions (29). IL-8 is generally recognized as a key intermediate regulator in acute inflammatory responses (30). TNF-α is an important mediator produced by activated macrophages and was shown to affect various biological processes, including the regulation and the production of other cytokines (31,32). Our findings revealed that PLE inhibits the dendritic transformation of RAW264.7 cells and the expression of IL-6, IL-8 and TNF-α in LPS-stimulated RAW264.7 cells, suggesting that PLE may attenuate the LPS-induced activation of macrophages and the consequent production of inflammatory cytokines.
NO is an important mediator and regulator involved in inflammatory responses. In activated inflammatory cells, NO is produced at high levels by iNOS. COX-2 is regarded as a central mediator of inflammation, and regulation of COX-2 was suggested to be useful in the development of a therapeutic target (33). Moreover, the enzymatic activity of COX-2 is directly affected by NO and iNOS (34,35). Our results showed that PLE inhibits both COX-2 and iNOS expression, as well as NO production, which further supports that PLE can attenuate the inflammatory response.
LPS is known to activate several signaling kinases, including ERK1/2, MEK (36), JNK, AP-1 (22), p38 and other MAP kinase family members (37). Our findings show that PLE inhibits iNOS expression and NO production in LPS-stimulated RAW264.7 cells, which may relate to the downregulation of NF-κB signaling components, including ERK1/2, JNK and p38. The inhibitory effect of PLE on NF-κB, ERK1/2 and JNK expression is crucial for the expression of iNOS.
In conclusion, the results from the present study indicate that PLE displays important anti-inflammatory activity in LPS-stimulated macrophage RAW264.7 cells, through inhibition of the expression of pro-inflammatory cytokines, inhibition of MAPK activation, and of NF-κB nuclear translocation in response to LPS.
Acknowledgements
This study was partly supported by grants from the National Science Council, Taiwan (nos. NSC99-2320-B-040-003-MY3 and NSC99-2632-B-040-001-MY3).
References
Ueda H and Yamazaki M: Inhibition of tumor necrosis factor-alpha production by orally administering a Perilla leaf extract. Biosci Biotechnol Biochem. 61:1292–1295. 1997. View Article : Google Scholar : PubMed/NCBI | |
Makino T, Ono T, Muso E, Honda G and Sasayama S: Suppressive effects of Perilla frutescens on spontaneous IgA nephropathy in ddY mice. Nephron. 83:40–46. 1999. | |
Ueda H and Yamazaki M: Anti-inflammatory and anti-allergic actions by oral administration of a Perilla leaf extract in mice. Biosci Biotechnol Biochem. 65:1673–1675. 2001. View Article : Google Scholar : PubMed/NCBI | |
Shin TY, Kim SH, Kim SH, et al: Inhibitory effect of mast cell-mediated immediate-type allergic reactions in rats by Perilla frutescens. Immunopharmacol Immunotoxicol. 22:489–500. 2000. View Article : Google Scholar : PubMed/NCBI | |
Hortelano S, Zeini M and Bosca L: Nitric oxide and resolution of inflammation. Methods Enzymol. 359:459–465. 2002. View Article : Google Scholar : PubMed/NCBI | |
Paige JS and Jaffrey SR: Pharmacologic manipulation of nitric oxide signaling: targeting NOS dimerization and protein-protein interactions. Curr Top Med Chem. 7:97–114. 2007. View Article : Google Scholar : PubMed/NCBI | |
Gao YT, Panda SP, Roman LJ, Martasek P, Ishimura Y and Masters BS: Oxygen metabolism by neuronal nitric-oxide synthase. J Biol Chem. 282:7921–7929. 2007. View Article : Google Scholar : PubMed/NCBI | |
Breitbach K, Klocke S, Tschernig T, van Rooijen N, Baumann U and Steinmetz I: Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice. Infect Immun. 74:6300–6309. 2006. View Article : Google Scholar : PubMed/NCBI | |
Cunha IW, Lopes A, Falzoni R and Soares FA: Sarcomas often express constitutive nitric oxide synthases (NOS) but infrequently inducible NOS. Appl Immunohistochem Mol Morphol. 14:404–410. 2006. View Article : Google Scholar : PubMed/NCBI | |
Farley KS, Wang LF, Razavi HM, et al: Effects of macrophage inducible nitric oxide synthase in murine septic lung injury. Am J Physiol Lung Cell Mol Physiol. 290:L1164–L1172. 2006. View Article : Google Scholar : PubMed/NCBI | |
Sacco RE, Waters WR, Rudolph KM and Drew ML: Comparative nitric oxide production by LPS-stimulated monocyte-derived macrophages from Ovis canadensis and Ovis aries. Comp Immunol Microbiol Infect Dis. 29:1–11. 2006. View Article : Google Scholar : PubMed/NCBI | |
Rahman A, Yatsuzuka R, Jiang S, Ueda Y and Kamei C: Involvement of cyclooxygenase-2 in allergic nasal inflammation in rats. Int Immunopharmacol. 6:1736–1742. 2006. View Article : Google Scholar : PubMed/NCBI | |
Geng Y, Zhang B and Lotz M: Protein tyrosine kinase activation is required for lipopolysaccharide induction of cytokines in human blood monocytes. J Immunol. 151:6692–6700. 1993.PubMed/NCBI | |
Kim HS, Ye SK, Cho IH, et al: 8-hydroxydeoxyguanosine suppresses NO production and COX-2 activity via Rac1/STATs signaling in LPS-induced brain microglia. Free Radic Biol Med. 41:1392–1403. 2006. View Article : Google Scholar : PubMed/NCBI | |
Park HJ, Kim IT, Won JH, et al: Anti-inflammatory activities of ent-16alphaH,17-hydroxy-kauran-19-oic acid isolated from the roots of Siegesbeckia pubescens are due to the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB inactivation. Eur J Pharmacol. 558:185–193. 2007. View Article : Google Scholar : PubMed/NCBI | |
Nakano H, Shindo M, Sakon S, et al: Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA. 95:3537–3542. 1998. View Article : Google Scholar | |
Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS and Tannenbaum SR: Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 126:131–138. 1982. | |
Saxena RK, Vallyathan V and Lewis DM: Evidence for lipopolysaccharide-induced differentiation of RAW264.7 murine macrophage cell line into dendritic like cells. J Biosci. 28:129–134. 2003. View Article : Google Scholar : PubMed/NCBI | |
Onuchic AC, Machado CM, Saito RF, Rios FJ, Jancar S and Chammas R: Expression of PAFR as part of a prosurvival response to chemotherapy: a novel target for combination therapy in melanoma. Mediators Inflamm. 2012:1754082012. View Article : Google Scholar : PubMed/NCBI | |
Chen H, Ma F, Hu X, Jin T, Xiong C and Teng X: Elevated COX2 expression and PGE2 production by downregulation of RXRα in senescent macrophages. Biochem Biophys Res Commun. 440:157–162. 2013.PubMed/NCBI | |
Adesso S, Popolo A, Bianco G, et al: The uremic toxin indoxyl sulphate enhances macrophage response to LPS. PloS One. 8:e767782013. View Article : Google Scholar : PubMed/NCBI | |
Hambleton J, Weinstein SL, Lem L and DeFranco AL: Activation of c-Jun N-terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proc Natl Acad Sci USA. 93:2774–2778. 1996. View Article : Google Scholar : PubMed/NCBI | |
An H, Yu Y, Zhang M, et al: Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology. 106:38–45. 2002. View Article : Google Scholar : PubMed/NCBI | |
Wang W, Deng M, Liu X, Ai W, Tang Q and Hu J: TLR4 activation induces nontolerant inflammatory response in endothelial cells. Inflammation. 34:509–518. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tak PP and Firestein GS: NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 107:7–11. 2001. View Article : Google Scholar : PubMed/NCBI | |
Murakami A, Nishizawa T, Egawa K, et al: New class of linoleic acid metabolites biosynthesized by corn and rice lipoxygenases: suppression of proinflammatory mediator expression via attenuation of MAPK- and Akt-, but not PPARgamma-, dependent pathways in stimulated macrophages. Biochem Pharmacol. 70:1330–1342. 2005. View Article : Google Scholar | |
Fujiwara N and Kobayashi K: Macrophages in inflammation. Curr Drug Targets Inflamm Allergy. 4:281–286. 2005. View Article : Google Scholar | |
Heumann D and Roger T: Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta. 323:59–72. 2002. View Article : Google Scholar : PubMed/NCBI | |
Desai TR, Leeper NJ, Hynes KL and Gewertz BL: Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res. 104:118–123. 2002. View Article : Google Scholar : PubMed/NCBI | |
Noda A, Kinoshita K, Sakurai A, Matsumoto T, Mugishima H and Tanjoh K: Hyperglycemia and lipopolysaccharide decrease depression effect of interleukin 8 production by hypothermia: an experimental study with endothelial cells. Intensive Care Med. 34:109–115. 2008. View Article : Google Scholar : PubMed/NCBI | |
Hume DA, Underhill DM, Sweet MJ, Ozinsky AO, Liew FY and Aderem A: Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state. BMC Immunol. 2:112001. View Article : Google Scholar | |
Aggarwal BB, Shishodia S, Ashikawa K and Bharti AC: The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy. 1:327–341. 2002. View Article : Google Scholar : PubMed/NCBI | |
Tsatsanis C, Androulidaki A, Venihaki M and Margioris AN: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol. 38:1654–1661. 2006. View Article : Google Scholar : PubMed/NCBI | |
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK and Sethi G: Inflammation and cancer: how hot is the link? Biochem Pharmacol. 72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI | |
Korhonen R, Lahti A, Kankaanranta H and Moilanen E: Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy. 4:471–479. 2005. View Article : Google Scholar : PubMed/NCBI | |
Geppert TD, Whitehurst CE, Thompson P and Beutler B: Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med. 1:93–103. 1994.PubMed/NCBI | |
Han J, Lee JD, Bibbs L and Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 265:808–811. 1994. View Article : Google Scholar : PubMed/NCBI |